Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT)

Jane E. Norman, Fiona Mackenzie, Philip Owen, Helen Mactier, Kevin Hanretty, Sarah Cooper, Andrew Calder, Gary Mires, Peter Danielian, Stephen Sturgiss, Graeme MacLennan, Graham Tydeman, Steven Thornton, Bill Martin, James G. Thornton, James P. Neilson, John Norrie

Research output: Contribution to journalArticle (Academic Journal)

Abstract

Women with twin pregnancy are at high risk for spontaneous preterm delivery. Progesterone seems to be effective in reducing preterm birth in selected high-risk singleton pregnancies, albeit with no significant reduction in perinatal mortality and little evidence of neonatal benefit. We investigated the use of progesterone for prevention of preterm birth in twin pregnancy.Methods In this double-blind, placebo-controlled trial, 500 women with twin pregnancy were recruited from nine UK National Health Service clinics specialising in the management of twin pregnancy. Women were randomised, by permuted blocks of randomly mixed sizes, either to daily vaginal progesterone gel 90 mg (n=250) or to placebo gel (n=250) for 10 weeks from 24 weeks' gestation. All study personnel and participants were masked to treatment assignment for the duration of the study. The primary outcome was delivery or intrauterine death before 34 weeks' gestation. Analysis was by intention to treat. Additionally we undertook a meta-analysis of published and unpublished data to establish the efficacy of progesterone in prevention of early (
Original languageEnglish
Pages (from-to)2034-2040
Number of pages7
JournalThe Lancet
Volume373
Issue number9680
DOIs
Publication statusPublished - 2009

Bibliographical note

RIS file

Fingerprint Dive into the research topics of 'Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT)'. Together they form a unique fingerprint.

Cite this